Contribute Try STAT+ Today

If a prescription drug needs a hard sell, can it really be all that good?

A new analysis suggests the answer is no, at least in Canada.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • There is a reason why drug reps do not promote the drugs on the WHO EML. All of the meds on the list from what I can see are generic. With the typical pharma company paying $3000 or more a day for one rep to visit 10 docs it it doesn’t make sense for them to be pushing generics. One also might argue the definition of “essential”. For example there are no TNF inhibitors on the list for rheumatoid arthritis, just the ones I learned about when I took pharmacology 45 years ago.

Comments are closed.